Drugmaker Bristol-Myers to buy Celgene for $74 billion


Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion in a cash-and-stock deal, creating a powerhouse that will have several blockbuster cancer drugs.